GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Rating of “Hold” by Analysts

GSK PLC Sponsored ADR (NYSE:GSK) has earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $53.00.

A number of research analysts recently commented on the company. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Weiss Ratings downgraded GSK from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 11th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of GSK in a report on Tuesday, June 9th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. First Horizon Corp raised its stake in GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 236 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in GSK during the fourth quarter valued at approximately $30,000. Triumph Capital Management acquired a new stake in GSK during the third quarter valued at approximately $40,000. 1248 Management LLC raised its stake in GSK by 314.6% during the third quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock valued at $46,000 after buying an additional 799 shares in the last quarter. Finally, Coston McIsaac & Partners raised its stake in GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after buying an additional 206 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.1%

Shares of GSK opened at $50.70 on Tuesday. The company has a market capitalization of $102.68 billion, a P/E ratio of 13.18, a P/E/G ratio of 2.62 and a beta of 0.36. GSK has a one year low of $35.45 and a one year high of $61.69. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79. The stock has a 50-day moving average price of $52.51 and a 200 day moving average price of $52.87.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be issued a $0.44 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.76 dividend on an annualized basis and a yield of 3.5%. GSK’s dividend payout ratio is currently 47.01%.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.